Loading…
As of 9 Nov 2026: Concord Biotech ₹596.80 (m-cap ₹12,533 Cr, P/E 44.3) vs Marksans Pharma ₹308.75 (m-cap ₹13,979 Cr, P/E 27.0). Compare ROE, ROCE, growth, debt, dividends and 1-year returns.
As of · NSE prices; ratios from company filings
| Metric | Concord Biotech | Marksans Pharma |
|---|---|---|
| Share price | ₹596.80 | ₹308.75 |
| Day change | −2.52% | +1.65% |
| Market cap | ₹12,533 Cr | ₹13,979 Cr |
| P/EPrice ÷ trailing 12-month earnings per share; blank for a loss. | 44.3 | 27.0 |
| P/BPrice ÷ book value per share. | 3.1 | 4.6 |
| ROEReturn on equity. | 12.5% | 15.2% |
| ROCEReturn on capital employed. | 17.0% | 19.0% |
| Sales growth (3Y CAGR) | 7.4% | — |
| Profit growth (3Y CAGR) | 0.2% | — |
| Debt to equity | 0.00 | 0.11 |
| Dividend yield | 0.63% | 0.29% |
| 1-year price return | −14.4% | +68.8% |
| Promoter holding | 44.1% | — |
| Industry | Pharmaceuticals | Pharmaceuticals |
Open in the compare tool for price charts from one month to five years, scorecards and more companies.
Each line states which company has the higher or lower figure; none of them is a recommendation.
Marksans Pharma Ltd is larger, with a market cap of ₹13,979 Cr against ₹12,533 Cr for Concord Biotech Ltd as of 9 Nov 2026 — about 1.1 times the size.
Marksans Pharma Ltd trades at a P/E of 27.0 against 44.3 for Concord Biotech Ltd as of 9 Nov 2026. A lower P/E alone does not make a share cheaper in value terms: growth, return on capital and debt differ between companies.
Jivani Markets does not give buy, sell or hold recommendations and is not a SEBI-registered investment adviser or research analyst. The table on this page lays out the facts side by side — price, valuation, returns on capital, growth, debt, dividends and promoter holding — so you can weigh them against your own goals, or with a SEBI-registered adviser.
Prices refresh every few minutes during market hours (delayed by up to 15 minutes) and ratios update when the companies report results. Each number is the same one shown on the two stock pages.